Las Vegas & East Rutherford, NJ – New Series of Benzoyl Peroxide with Invisicare Formulations Available
Skinvisible, Inc. (OTC Bulletin Board: SKVI), the developers of Invisicare, a patented polymer delivery system that enhances topical skincare products, andCambrex Corporation, (NYSE: CBM, “Cambrex”) a leading provider of products and services to the pharmaceutical industry, announced today that they have signed a joint marketing and development agreement. The agreement provides for research and development into acne formulations based on Skinvisible’s Invisicare technology and benzoyl peroxide (BPO) manufactured by Cambrex. In addition, the two companies will share marketing responsibilities for the products that are developed under this agreement.
“Invisicare is a technology that adds many advantages to active ingredients. Our recent developments with Cambrex’s BPO in strengths of 2.5%, 5% and 10% along with the BPO combination formulations we are developing, has given us a whole new series of acne products to license worldwide,” said Terry Howlett, President and CEO of Skinvisible Pharmaceuticals. “We have proven that we can control the release of active ingredients such as BPO with Invisicare and this can result in use of less active ingredient, less irritation and better efficacy. Additionally, Invisicare can hold ingredients on the skin allowing acne sufferers to benefit from the treatment for a longer period of time.” He added, “We are confident that our collaboration with Cambrex will be beneficial to both parties as we have complementary ingredients that when combined, benefit from each other.”
“Cambrex produces a high-grade benzoyl peroxide API that is made under cGMP and which has a Drug Master File (DMF),” said Steve Klosk, President and CEO of Cambrex Corporation. “This collaboration with Skinvisible will enable us to provide our clients with technology-enhanced delivery options for our BPO products. We are excited to have the opportunity to associate our API with Skinvisible’s innovative technology. We foresee that this value-added approach is an advantage for our clients and acne patients.”
Invisicare is Skinvisible’s patented polymer delivery system that offers “life-cycle management” and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash-off and perspiration. Invisicare controls the release of actives, reducing irritation and eliminating some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development, license, and royalties fees for the life of the Invisicare patent. www.skinvisible.com
Skinvisible Pharmaceuticals, Inc. Forward-Looking Statements
This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending September 30, 2008).
CambrexCorporation Forward-Looking Statements
This news release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that words such as “expects”, “anticipates”, “intends”, “estimates”, “believes” or similar expressions are used in connection with any discussion of future financial or operating performance. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in the Company’s periodic reports filed with the U.S. Securities and Exchange Commission. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation or regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company’s public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company’s ability to receive regulatory approvals for its products and the accuracy of the Company’s current estimates with respect to its earnings and profits for tax purposes in 2007. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time and it is not possible for the Company to predict which new factors will arise. In addition, we cannot assess the impact of each factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
For further details and a discussion of these and other risks and uncertainties, investors and security holders are cautioned to review the Cambrex 2007 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other subsequent filings with the U.S. Securities and Exchange Commission, including Current Reports on Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Skinvisible Corporate Contact
Doreen McMorran, VP Business Development
Skinvisible Pharmaceuticals, Inc.